Overview

Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This study enrolled 94 patients with UC or CD. Two groups received either 8-week intestinal bacterial transplant capsule therapy or biological therapy, respectively. The control group received biological therapy alone, while the experimental group received biological therapy combined with FMT. Both groups were followed up for 52 weeks after discharge. The efficacy of FMT capsule therapy on the subjects' UC or CD symptom-related scores and its effect on remodeling the intestinal flora were observed, and its safety was verified.
Phase:
NA
Details
Lead Sponsor:
Shanghai 10th People's Hospital
Treatments:
Biological Factors
Fecal Microbiota Transplantation
Infliximab